Ad is loading...
NTLA
Price
$13.97
Change
-$1.15 (-7.61%)
Updated
Nov 15 closing price
95 days until earnings call
PTCT
Price
$39.23
Change
-$3.15 (-7.43%)
Updated
Nov 15 closing price
100 days until earnings call
Ad is loading...

NTLA vs PTCT

Header iconNTLA vs PTCT Comparison
Open Charts NTLA vs PTCTBanner chart's image
Intellia Therapeutics
Price$13.97
Change-$1.15 (-7.61%)
Volume$3.69M
CapitalizationN/A
PTC Therapeutics
Price$39.23
Change-$3.15 (-7.43%)
Volume$1.04M
CapitalizationN/A
NTLA vs PTCT Comparison Chart
Loading...
NTLA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
PTCT
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
NTLA vs. PTCT commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NTLA is a StrongSell and PTCT is a StrongSell.

COMPARISON
Comparison
Nov 18, 2024
Stock price -- (NTLA: $13.97 vs. PTCT: $39.23)
Brand notoriety: NTLA and PTCT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NTLA: 159% vs. PTCT: 133%
Market capitalization -- NTLA: $1.42B vs. PTCT: $3.03B
NTLA [@Biotechnology] is valued at $1.42B. PTCT’s [@Biotechnology] market capitalization is $3.03B. The market cap for tickers in the [@Biotechnology] industry ranges from $472.8B to $0. The average market capitalization across the [@Biotechnology] industry is $2.66B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NTLA’s FA Score shows that 1 FA rating(s) are green whilePTCT’s FA Score has 0 green FA rating(s).

  • NTLA’s FA Score: 1 green, 4 red.
  • PTCT’s FA Score: 0 green, 5 red.
According to our system of comparison, both NTLA and PTCT are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NTLA’s TA Score shows that 5 TA indicator(s) are bullish while PTCT’s TA Score has 2 bullish TA indicator(s).

  • NTLA’s TA Score: 5 bullish, 4 bearish.
  • PTCT’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, NTLA is a better buy in the short-term than PTCT.

Price Growth

NTLA (@Biotechnology) experienced а -16.50% price change this week, while PTCT (@Biotechnology) price change was -11.40% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.58%. For the same industry, the average monthly price growth was -5.90%, and the average quarterly price growth was -0.16%.

Reported Earning Dates

NTLA is expected to report earnings on Feb 20, 2025.

PTCT is expected to report earnings on Feb 25, 2025.

Industries' Descriptions

@Biotechnology (-8.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PTCT($3.03B) has a higher market cap than NTLA($1.42B). PTCT YTD gains are higher at: 42.344 vs. NTLA (-54.182). PTCT has higher annual earnings (EBITDA): -132.14M vs. NTLA (-514.18M). PTCT has more cash in the bank: 1.09B vs. NTLA (691M). NTLA has less debt than PTCT: NTLA (106M) vs PTCT (396M). PTCT has higher revenues than NTLA: PTCT (900M) vs NTLA (46M).
NTLAPTCTNTLA / PTCT
Capitalization1.42B3.03B47%
EBITDA-514.18M-132.14M389%
Gain YTD-54.18242.344-128%
P/E RatioN/AN/A-
Revenue46M900M5%
Total Cash691M1.09B63%
Total Debt106M396M27%
FUNDAMENTALS RATINGS
NTLA vs PTCT: Fundamental Ratings
NTLA
PTCT
OUTLOOK RATING
1..100
875
VALUATION
overvalued / fair valued / undervalued
1..100
33
Fair valued
99
Overvalued
PROFIT vs RISK RATING
1..100
9695
SMR RATING
1..100
95100
PRICE GROWTH RATING
1..100
9339
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (33) in the Biotechnology industry is significantly better than the same rating for PTCT (99). This means that NTLA’s stock grew significantly faster than PTCT’s over the last 12 months.

PTCT's Profit vs Risk Rating (95) in the Biotechnology industry is in the same range as NTLA (96). This means that PTCT’s stock grew similarly to NTLA’s over the last 12 months.

NTLA's SMR Rating (95) in the Biotechnology industry is in the same range as PTCT (100). This means that NTLA’s stock grew similarly to PTCT’s over the last 12 months.

PTCT's Price Growth Rating (39) in the Biotechnology industry is somewhat better than the same rating for NTLA (93). This means that PTCT’s stock grew somewhat faster than NTLA’s over the last 12 months.

PTCT's P/E Growth Rating (100) in the Biotechnology industry is in the same range as NTLA (100). This means that PTCT’s stock grew similarly to NTLA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NTLAPTCT
RSI
ODDS (%)
Bullish Trend 3 days ago
84%
Bearish Trend 3 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
87%
Bearish Trend 3 days ago
80%
Momentum
ODDS (%)
Bearish Trend 3 days ago
82%
Bearish Trend 3 days ago
71%
MACD
ODDS (%)
Bullish Trend 3 days ago
76%
Bearish Trend 3 days ago
78%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
78%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
88%
Bullish Trend 3 days ago
78%
Advances
ODDS (%)
Bullish Trend 7 days ago
78%
Bullish Trend 7 days ago
76%
Declines
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 3 days ago
79%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
90%
Bearish Trend 3 days ago
86%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
77%
View a ticker or compare two or three
Ad is loading...
NTLA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
PTCT
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TOLIX16.770.15
+0.90%
DWS RREEF Global Infrastructure Inst
PREAX6.95N/A
N/A
PACE Global Real Estate Securities A
RDERX18.01-0.07
-0.39%
Columbia Large Cap Value Adv
MCBVX32.79-0.22
-0.67%
MFS Mid Cap Value B
DBOCX24.71-0.22
-0.88%
BNY Mellon Balanced Opportunity C

NTLA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NTLA has been closely correlated with VCYT. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if NTLA jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTLA
1D Price
Change %
NTLA100%
-7.61%
VCYT - NTLA
69%
Closely correlated
-2.97%
EDIT - NTLA
68%
Closely correlated
-3.97%
BEAM - NTLA
67%
Closely correlated
-8.59%
CRSP - NTLA
64%
Loosely correlated
+0.85%
PRME - NTLA
58%
Loosely correlated
-6.95%
More

PTCT and

Correlation & Price change

A.I.dvisor indicates that over the last year, PTCT has been loosely correlated with DYN. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if PTCT jumps, then DYN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PTCT
1D Price
Change %
PTCT100%
-7.43%
DYN - PTCT
43%
Loosely correlated
-6.33%
PGEN - PTCT
41%
Loosely correlated
-7.11%
XNCR - PTCT
41%
Loosely correlated
-1.83%
ABSI - PTCT
40%
Loosely correlated
-5.80%
NTLA - PTCT
40%
Loosely correlated
-7.61%
More